Avenue Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ATXI Nasdaq 2834 http://www.avenuetx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Avenue Therapeutics Inc

Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights - Mar 30th, 2023 8:10 pm
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights - Mar 30th, 2023 8:01 pm
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates - Mar 8th, 2023 9:01 pm
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy - Mar 2nd, 2023 1:00 pm
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI) - Jan 31st, 2023 6:30 pm
Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement - Jan 31st, 2023 6:09 pm
Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules - Jan 27th, 2023 4:58 pm
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights - Nov 10th, 2022 9:10 pm
Avenue Therapeutics Buys Baergic Bio, Beefs Up Central Nervous System-Focused Portfolio - Nov 8th, 2022 5:26 pm
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders - Nov 8th, 2022 1:30 pm
Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI) - Oct 12th, 2022 2:25 pm
Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering - Oct 11th, 2022 6:15 pm
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering - Oct 7th, 2022 3:00 am
Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer - Oct 3rd, 2022 12:00 pm
Avenue Therapeutics Announces Reverse Stock Split, Regulatory Update For Lead Its Pain Candidate - Sep 23rd, 2022 12:51 pm
Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA - Sep 22nd, 2022 8:25 pm